Close
Top Videos
Top Searches
Moods
Black Lives Matter
Chill
Christmas
Commute
Energy boosters
Feel-Good
Focus
Party
Pride
Romance
Sad
Sleep
Workout
Genres
African
Arabic
Blues
Bollywood & Indian
Christian & Gospel
Classical
Country and Americana
Dance and electronic
Decades
Family
Folk and acoustic
Hip-hop
Indie and alternative
J-Pop
Jazz
K-Pop
Latin
Mandopop & Cantopop
Metal
Pop
R&B and Soul
Reggae and Caribbean
Rock
Soundtracks and musicals
Moving away from chemoimmunotherapy and towards novel targeted agents in CLL
02:56
|
Download MP3
Related Videos
5:11
iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma
3:08
Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸
1:31
Frontline treatment for CLL: the changing paradigm
1:36
The use of outpatient cilta-cel in the treatment of multiple myeloma
1:32
Unanswered questions in MCL: when will we achieve cure?
3:02
The role of asparaginase in the treatment of ALL
1:53
Challenges in developing immunotherapies for CLL compared to other hematologic malignancies
5:40
Recommendations for biomarker analysis in CLL: updates from ERIC 2024
4:45
Increasing diversity in myeloma clinical trials: addressing disparities & inclusion criteria
1:20
Insights into the diagnosis of smoldering myeloma from a UK perspective & ongoing trials
2:22
The need for novel agents to treat patients with MCL who have relapsed after targeted therapy
1:14
Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics
4:48
The evolution of alloSCT in Richter's transformation and its combination with biological agents
1:59
Assessing if a patient with DLBCL is responding to treatment using PET-CT and novel assays
2:55
A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib
6:54
Biomarker-guided treatment of CLL in the chemo-free era
2:13
Personalizing the timing of SCT in patients with myelofibrosis
2:57
Moving away from chemoimmunotherapy and towards novel targeted agents in CLL
1:22
Responses to olutasidenib in patients with AML who have failed treatment with venetoclax
0:44
Early detection and interception across hematological cancers